⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for metastatic renal cell carcinoma

Every month we try and update this database with for metastatic renal cell carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney CancerNCT00095108
Melanoma
Kidney Neoplasm...
Metastases
Recombinant Hum...
18 Years - ZymoGenetics
M8891 First in Human in Solid TumorsNCT03138538
Advanced Solid ...
Metastatic Rena...
Part 1: M8891
18 Years - EMD Serono
Retrospective Analysis Of Progression Free Survival And Overall Survival In A National Cohort Of Patients With Metastatic Renal Cell Carcinoma Treated In Denmark From 2006-2010. DARENCA Study 2.NCT01339962
Renal Cell Carc...
Non-interventio...
18 Years - Pfizer
Efficacy and Safety of Bevacizumab Plus Sorafenib for the Third-line Treatment in Metastatic Renal Cancer PatientsNCT02330783
Metastatic Rena...
Bevacizumab
Sorafenib
18 Years - 75 YearsPeking University Cancer Hospital & Institute
UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint BlockadeNCT03474497
Non Small Cell ...
Metastatic Mela...
Metastatic Rena...
Head and Neck S...
IL-2
Pembrolizumab
Radiotherapy
18 Years - University of California, Davis
Everolimus as Second-line Therapy in Metastatic Renal Cell CarcinomaNCT01491672
Metastatic Rena...
RAD001
18 Years - Novartis
CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney CancerNCT05122546
Advanced Clear ...
Advanced Papill...
Advanced Renal ...
Advanced Sarcom...
Metastatic Clea...
Metastatic Papi...
Metastatic Rena...
Metastatic Sarc...
Stage III Renal...
Stage IV Renal ...
Unresectable Cl...
Unresectable Re...
Cabozantinib S-...
Clostridium but...
Nivolumab
18 Years - City of Hope Medical Center
Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2NCT03284385
Clear Cell Rena...
Locally Advance...
Locally Advance...
Metastatic Mali...
Metastatic Rena...
Stage III Renal...
Stage IV Renal ...
Adavosertib
18 Years - National Cancer Institute (NCI)
Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing NephrectomyNCT03055013
Metastatic Rena...
Sarcomatoid Ren...
Stage II Renal ...
Stage III Renal...
Unclassified Re...
Nephrectomy
Nivolumab
Patient Observa...
18 Years - National Cancer Institute (NCI)
Trial Of Sunitinib In Advanced Non-Clear Cell Type Renal Cell CarcinomaNCT01219751
Metastatic Rena...
Sunitinib
18 Years - Asan Medical Center
Study of M200 (Volociximab) in Patients With Metastatic Renal Cell Carcinoma (RCC)NCT00100685
Renal Cell Carc...
Metastases
Volociximab (an...
18 Years - Abbott
Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and Metastatic Kidney CancerNCT06391099
Clinical Stage ...
Metastatic Cuta...
Metastatic Rena...
Stage IV Renal ...
Best Practice
Biospecimen Col...
Computed Tomogr...
Dietary Interve...
Educational Act...
Glucose Measure...
Ketone Measurem...
Questionnaire A...
18 Years - Ohio State University Comprehensive Cancer Center
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLCNCT04140526
Non Small Cell ...
Advanced Solid ...
Metastatic Mela...
Metastatic Head...
Metastatic Rena...
Metastatic Colo...
Sarcomas
Metastatic Pros...
Ovarian Cancer
Small Cell Lung...
Metastatic Brea...
Pancreas Cancer
Gastric Cancer
Esophageal Canc...
Gastroesophagea...
Cervical Cancer
Adenoid Cystic ...
Salivary Gland ...
Urothelial Carc...
ONC-392
Pembrolizumab
Docetaxel
18 Years - OncoC4, Inc.
Study of M200 (Volociximab) in Patients With Metastatic Renal Cell Carcinoma (RCC)NCT00100685
Renal Cell Carc...
Metastases
Volociximab (an...
18 Years - Abbott
Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and Metastatic Kidney CancerNCT06391099
Clinical Stage ...
Metastatic Cuta...
Metastatic Rena...
Stage IV Renal ...
Best Practice
Biospecimen Col...
Computed Tomogr...
Dietary Interve...
Educational Act...
Glucose Measure...
Ketone Measurem...
Questionnaire A...
18 Years - Ohio State University Comprehensive Cancer Center
Real-world Clinical Patterns Of Care And Outcomes Among AfME mRCC Patients Receiving Sunitinib as First Line Therapy.NCT03140176
Metastatic Rena...
Sunitinib
18 Years - Pfizer
Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell CarcinomaNCT04974671
Renal Cell Carc...
Metastatic Rena...
Oligoprogressiv...
Progression
Stereotactic Bo...
18 Years - Yale University
Safety of RAD001 in Chinese Patients With Metastatic Renal Cell CancerNCT01152801
Metastatic Rena...
Everolimus (RAD...
18 Years - Novartis
Occupational Therapy Fatigue Management-Based Intervention for Metastatic Renal Cell CarcinomaNCT04961320
Metastatic Rena...
Stage IV Renal ...
Occupational Th...
Questionnaire A...
18 Years - City of Hope Medical Center
Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney CancerNCT00923845
Renal Cell Carc...
Graft-Versus-Ho...
Engraftment Syn...
Pentostatin
Sirolimus
Cyclophosphamid...
Allogeneic Hema...
Th2 rapa cells
Donor Lymphocyt...
Induction Thera...
GVHD prophylaxi...
Donor Hematopoi...
18 Years - 75 YearsNational Institutes of Health Clinical Center (CC)
Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain MetastasesNCT03967522
Metastatic Rena...
Cabozantinib
18 Years - Centre Leon Berard
Pazopanib in Second-line Therapy in Renal Cell CarcinomaNCT01577784
Metastatic Rena...
Pazopanib
18 Years - Associació per a la Recerca Oncologica, Spain
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell CarcinomaNCT01265901
Metastatic Rena...
Sunitinib
GM-CSF
Cyclophosphamid...
IMA901
18 Years - Immatics Biotechnologies GmbH
Decitabine Combined With Oxaliplatin in Patients With Advanced Renal Cell CarcinomaNCT04049344
Metastatic Rena...
Decitabine; Oxa...
18 Years - 75 YearsZhejiang Cancer Hospital
App-Based Mindfulness Intervention for the Improvement of Quality of Life in Patients With Metastatic Renal Cell CancerNCT04788095
Metastatic Rena...
Stage IV Renal ...
Behavioral Inte...
Quality-of-Life...
Questionnaire A...
18 Years - City of Hope Medical Center
Cytokines in Patients With Metastatic Renal Cell Carcinoma of Intermediate PrognosisNCT00291369
Metastatic Rena...
Interleukin-2
Interferon alfa
medroxyprogeste...
18 Years - Centre Leon Berard
Trial of G250 Peptide and IL-2 Following Surgical Resection of Locally Advanced/Metastatic Renal Cell CarcinomaNCT00203866
Metastatic Rena...
G250 peptide
IL-2
18 Years - University of Chicago
Vascular Endothelial Growth Factor (VEGF) Imaging Before and During Everolimus Treatment for Renal Cell CarcinomaNCT01028638
Metastatic Rena...
89Zr-bevacizuma...
18 Years - University Medical Center Groningen
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the LungsNCT06228326
Lung Cancer, No...
Lung Cancer Met...
Solid Tumor, Ad...
Advanced Cancer
Lung Cancer, Sm...
Metastatic Colo...
Metastatic Rena...
Metastatic Hepa...
Metastatic Sarc...
Metastatic Oste...
KB707
18 Years - Krystal Biotech, Inc.
Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain MetastasesNCT03967522
Metastatic Rena...
Cabozantinib
18 Years - Centre Leon Berard
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in MalignancyNCT01415167
Metastatic Rena...
Metastatic Mela...
18 Years - Prometheus Laboratories
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced MalignanciesNCT02419495
Advanced Malign...
Clinical Stage ...
Clinical Stage ...
Fallopian Tube ...
Metastatic Lung...
Metastatic Mali...
Metastatic Mela...
Metastatic Rena...
Ovarian Carcino...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Primary Periton...
Stage III Lung ...
Stage III Renal...
Stage IIIA Lung...
Stage IIIB Lung...
Stage IIIC Lung...
Stage IV Lung C...
Stage IV Renal ...
Stage IVA Lung ...
Stage IVB Lung ...
Triple-Negative...
Unresectable Lu...
Unresectable Me...
Unresectable Re...
Capecitabine
Carboplatin
Cyclophosphamid...
Doxorubicin
Eribulin
Fluorouracil
Ipilimumab
Irinotecan Hydr...
Leucovorin Calc...
Nivolumab
Olaparib
Oxaliplatin
Paclitaxel
Pembrolizumab
Pemetrexed
Selinexor
Topotecan
18 Years - M.D. Anderson Cancer Center
Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise TestingNCT03109015
Carcinoma, Rena...
Sunitinib
Sunitinib
18 Years - Duke University
Retrospective Analysis Of Progression Free Survival And Overall Survival In A National Cohort Of Patients With Metastatic Renal Cell Carcinoma Treated In Denmark From 2006-2010. DARENCA Study 2.NCT01339962
Renal Cell Carc...
Non-interventio...
18 Years - Pfizer
Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC)NCT02454478
Carcinoma, Rena...
Lenvatinib
Everolimus
20 Years - Eisai Inc.
Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2)NCT01266837
Metastatic Rena...
Failure of Exac...
Everolimus
18 Years - iOMEDICO AG
Urine Omics Predicting IO Therapy Responses in mRCC PatientsNCT04712305
Metastatic Rena...
No intervention...
20 Years - National Taiwan University Hospital
Testing the Addition of Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in People With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic RadiosurgeryNCT04588246
Anatomic Stage ...
Metastatic Brea...
Metastatic Dige...
Metastatic Lung...
Metastatic Mali...
Metastatic Mela...
Metastatic Rena...
Prognostic Stag...
Recurrent Brain...
Stage IV Lung C...
Stage IV Renal ...
Stage IVA Lung ...
Stage IVB Lung ...
Memantine
Quality-of-Life...
Questionnaire A...
Stereotactic Ra...
Whole-Brain Rad...
18 Years - NRG Oncology
Safety and Preliminary Efficacy of SBRT in Patients With Metastatic RCC Treated With Targeted or IO TherapyNCT02864615
Metastatic Rena...
SBRT
18 Years - 75 YearsKidney Cancer Research Bureau
Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell CarcinomaNCT00630409
Metastatic Rena...
Gemcitabine
Doxil
18 Years - University of Pittsburgh
Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent NivolumabNCT03149159
Clear Cell Rena...
Metastatic Rena...
Nivolumab
Ipilimumab
Steriotactic ra...
18 Years - Medical University of South Carolina
Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCCNCT00522249
Carcinoma, Rena...
Pegylated Alfa ...
sunitinib
erlotinib
18 Years - The Methodist Hospital Research Institute
Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney CancerNCT03587662
Metastatic Kidn...
Metastatic Rena...
SMARCB1 Negativ...
Stage III Renal...
Stage IV Renal ...
Doxorubicin
Doxorubicin Hyd...
Gemcitabine
Gemcitabine Hyd...
Ixazomib
Ixazomib Citrat...
12 Years - M.D. Anderson Cancer Center
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIVNCT04514484
Advanced Differ...
Advanced Head a...
Advanced Hepato...
Advanced Kaposi...
Advanced Lung N...
Advanced Lung S...
Advanced Malign...
Advanced Melano...
Advanced Ovaria...
Advanced Prosta...
Advanced Renal ...
Advanced Thyroi...
Advanced Triple...
Advanced Urothe...
Anatomic Stage ...
Anatomic Stage ...
Castration-Resi...
Clinical Stage ...
Clinical Stage ...
HIV Infection
Metastatic Diff...
Metastatic Head...
Metastatic Hepa...
Metastatic Kapo...
Metastatic Lung...
Metastatic Lung...
Metastatic Mali...
Metastatic Mela...
Metastatic Ovar...
Metastatic Pros...
Metastatic Rena...
Metastatic Thyr...
Metastatic Trip...
Metastatic Urot...
Recurrent Diffe...
Recurrent Head ...
Recurrent Hepat...
Recurrent Kapos...
Recurrent Lung ...
Recurrent Lung ...
Recurrent Malig...
Recurrent Melan...
Recurrent Ovari...
Recurrent Prost...
Recurrent Renal...
Recurrent Thyro...
Recurrent Tripl...
Recurrent Uroth...
Refractory Diff...
Stage III Diffe...
Stage III Hepat...
Stage III Lung ...
Stage III Ovari...
Stage III Prost...
Stage III Renal...
Stage III Thyro...
Stage IV Differ...
Stage IV Hepato...
Stage IV Lung C...
Stage IV Ovaria...
Stage IV Prosta...
Stage IV Renal ...
Stage IV Thyroi...
Biospecimen Col...
Cabozantinib S-...
Computed Tomogr...
Magnetic Resona...
Nivolumab
18 Years - National Cancer Institute (NCI)
Velcade and Sorafenib in Unresected or Metastatic Renal Cell CarcinomaNCT01100242
Metastatic Rena...
Velcade and Sor...
18 Years - New Mexico Cancer Care Alliance
Efficacy Study of Sunitinib and Everolimus (Rotational vs Sequential Arm) in Pats. With m Clear Cell Renal CancerNCT01784978
Metastatic Rena...
Sunitinib
Everolimus
18 Years - Associació per a la Recerca Oncologica, Spain
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney CancerNCT00357760
Metastatic Rena...
VEGF Trap
18 Years - National Cancer Institute (NCI)
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell CarcinomaNCT01223027
Metastatic Rena...
Dovitinib
Sorafenib
18 Years - Novartis
Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene MutationsNCT03786796
Renal Cell Carc...
Metastatic Rena...
Kidney Cancer
Renal Carcinoma
Kidney Cancer M...
Olaparib
18 Years - 120 YearsSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Testing the Addition of Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in People With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic RadiosurgeryNCT04588246
Anatomic Stage ...
Metastatic Brea...
Metastatic Dige...
Metastatic Lung...
Metastatic Mali...
Metastatic Mela...
Metastatic Rena...
Prognostic Stag...
Recurrent Brain...
Stage IV Lung C...
Stage IV Renal ...
Stage IVA Lung ...
Stage IVB Lung ...
Memantine
Quality-of-Life...
Questionnaire A...
Stereotactic Ra...
Whole-Brain Rad...
18 Years - NRG Oncology
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or ThoraxNCT05092373
Advanced Breast...
Advanced Endome...
Advanced Fallop...
Advanced Hepato...
Advanced Malign...
Advanced Malign...
Advanced Malign...
Advanced Ovaria...
Advanced Primar...
Advanced Renal ...
Anatomic Stage ...
Anatomic Stage ...
Anatomic Stage ...
Anatomic Stage ...
Anatomic Stage ...
Malignant Abdom...
Malignant Solid...
Metastatic Brea...
Metastatic Endo...
Metastatic Fall...
Metastatic Hepa...
Metastatic Mali...
Metastatic Mali...
Metastatic Mali...
Metastatic Ovar...
Metastatic Prim...
Metastatic Rena...
Prognostic Stag...
Prognostic Stag...
Prognostic Stag...
Prognostic Stag...
Prognostic Stag...
Stage III Fallo...
Stage III Hepat...
Stage III Ovari...
Stage III Prima...
Stage III Renal...
Stage III Uteri...
Stage IIIA Fall...
Stage IIIA Hepa...
Stage IIIA Ovar...
Stage IIIA Prim...
Stage IIIA Uter...
Stage IIIA1 Fal...
Stage IIIA1 Ova...
Stage IIIA2 Fal...
Stage IIIA2 Ova...
Stage IIIB Fall...
Stage IIIB Hepa...
Stage IIIB Ovar...
Stage IIIB Prim...
Stage IIIB Uter...
Stage IIIC Fall...
Stage IIIC Ovar...
Stage IIIC Prim...
Stage IIIC Uter...
Stage IIIC1 Ute...
Stage IIIC2 Ute...
Stage IV Fallop...
Stage IV Hepato...
Stage IV Ovaria...
Stage IV Primar...
Stage IV Renal ...
Stage IV Uterin...
Stage IVA Fallo...
Stage IVA Hepat...
Stage IVA Ovari...
Stage IVA Prima...
Stage IVA Uteri...
Stage IVB Fallo...
Stage IVB Hepat...
Stage IVB Ovari...
Stage IVB Prima...
Stage IVB Uteri...
Atezolizumab
Cabozantinib S-...
Nab-paclitaxel
Tumor Treating ...
18 Years - M.D. Anderson Cancer Center
Study of Sorafenib in Patients With Advanced Renal Cell CarcinomaNCT00848640
Metastatic Rena...
Sorafenib
18 Years - 60 YearsEgyptian Foundation For Cancer Research
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell CarcinomaNCT05263050
Metastatic Rena...
Clear-cell Meta...
Cabozantinib
Nivolumab
18 Years - Fox Chase Cancer Center
A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary CancersNCT03115801
Metastatic Rena...
Metastatic Urot...
Nivolumab
Atezolizumab
Radiation & imm...
Pembrolizumab
19 Years - 90 YearsWeill Medical College of Cornell University
Efficacy of Activated Lymphocytes in Renal Cell Carcinoma.NCT00151645
Metastatic Rena...
activated lymph...
18 Years - 70 YearsRennes University Hospital
Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell CarcinomaNCT04919122
Metastatic Rena...
19 Years - Duke University
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid TumorsNCT03682289
Clear Cell Rena...
Locally Advance...
Locally Advance...
Metastatic Mali...
Metastatic Rena...
Metastatic Urot...
Metastatic Panc...
Stage III Pancr...
Stage III Renal...
Stage IV Pancre...
Stage IV Renal ...
Endometrial Can...
Metastatic Cast...
Ceralasertib
Olaparib
Durvalumab
18 Years - University of California, San Francisco
Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell CarcinomaNCT01481870
Metastatic Rena...
Sorafenib-sunit...
Sunitinib-soraf...
20 Years - 80 YearsYamagata University
Talazoparib and Axitinib for People With Previously Treated Advanced Kidney CancerNCT04337970
Kidney Cancer
Renal Cell Carc...
Unresectable Re...
Metastatic Rena...
Talazoparib
Axitinib
18 Years - Memorial Sloan Kettering Cancer Center
Safety of RAD001 in Chinese Patients With Metastatic Renal Cell CancerNCT01152801
Metastatic Rena...
Everolimus (RAD...
18 Years - Novartis
Bevacizumab in Metastatic Renal CancerNCT02627144
Renal Cell Canc...
Bevacizumab
Interferon alph...
18 Years - Hoffmann-La Roche
TIL Therapy for Metastatic Renal Cell CarcinomaNCT02926053
Metastatic Rena...
Surgical remova...
Cyclophosphamid...
Fludarabine
TIL infusion
Interleukin-2
18 Years - 70 YearsHerlev Hospital
Epidemiological Study to Identify Prognosis and Predictive Biomarkers for Advanced or Metastatic Renal Cell CarcinomaNCT03519542
Metastatic Rena...
Sunitinib
18 Years - Spanish Oncology Genito-Urinary Group
A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)NCT06284564
Metastatic Rena...
Evolocumab
Nivolumab
18 Years - M.D. Anderson Cancer Center
MRI Study of BAY 43-9006 in Metastatic Renal Cell CarcinomaNCT00606866
Metastatic Rena...
placebo
Sorafenib
Sorafenib
18 Years - University of Chicago
Nivolumab in mRCC Patients: Treg Function, T-cell Access and NK Interactions to Predict and Improve EfficacyNCT03891485
RCC
Metastatic Rena...
Immunological a...
- National Cancer Institute, Naples
Stereotactic Radiotherapy for Metastatic Kidney Cancer Being Treated With SunitinibNCT02019576
Clear Cell Meta...
Stereotactic ra...
18 Years - Sunnybrook Health Sciences Centre
Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell CarcinomaNCT00056173
Carcinoma, Rena...
Metastases, Neo...
GTI-2040
18 Years - Aptose Biosciences Inc.
A Study of Ramucirumab in Participants With Metastatic Renal Cell CarcinomaNCT00515697
Metastatic Rena...
Ramucirumab
18 Years - Eli Lilly and Company
Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)NCT02060370
Genitourinary C...
Kidney Cancer
Sunitinib
Questionnaire
18 Years - M.D. Anderson Cancer Center
A SU011248 Expanded Access Protocol for Systemic Therapy of Patients With Metastatic Renal Cell Carcinoma Who Are Ineligible for Participation in Other SU011248 Protocols But May Derive Benefit From Treatment With SU011248NCT00531544
Metastatic Rena...
SU011248
18 Years - 85 YearsKing Faisal Specialist Hospital & Research Center
Matched Unrelated Donor Transplant for Metastatic Renal Cell CarcinomaNCT00318110
Metastatic Rena...
NST using MUD f...
18 Years - 65 YearsCenter for International Blood and Marrow Transplant Research
Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing NephrectomyNCT03055013
Metastatic Rena...
Sarcomatoid Ren...
Stage II Renal ...
Stage III Renal...
Unclassified Re...
Nephrectomy
Nivolumab
Patient Observa...
18 Years - National Cancer Institute (NCI)
Immunophenotyping in Metastatic Kidney Cancer Patients Receiving Ablative TherapyNCT05112627
Metastatic Rena...
Stage IV Renal ...
Biospecimen Col...
18 Years - Mayo Clinic
A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary CancersNCT03115801
Metastatic Rena...
Metastatic Urot...
Nivolumab
Atezolizumab
Radiation & imm...
Pembrolizumab
19 Years - 90 YearsWeill Medical College of Cornell University
A Research Study for Patients With Metastatic Renal Cell CarcinomaNCT00106613
Carcinoma, Rena...
Neoplasm Metast...
FK228 (romideps...
18 Years - Celgene
Application Circulating Tumor DNA Dynamic Monitoring in Clinical Treatment of Metastatic Renal Cell CarcinomaNCT05816642
Metastatic Rena...
sunitinib or pa...
PD-1 inhibitor ...
- RenJi Hospital
A Phase II Study of Axitinib in Patients With Metastatic Renal Cell Cancer Unsuitable for NephrectomyNCT01693822
Clear-cell Meta...
Axitinib
18 Years - Institute of Cancer Research, United Kingdom
Nivolumab in Treating Patients With High-Risk Kidney Cancer Before SurgeryNCT02595918
Clear Cell Rena...
Metastatic Rena...
Stage I Renal C...
Stage II Renal ...
Stage III Renal...
Stage IV Renal ...
Metastasectomy
Nephrectomy
Nivolumab
18 Years - National Cancer Institute (NCI)
Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell CarcinomaNCT03149822
Metastatic Rena...
Cabozantinib
Pembrolizumab
18 Years - 100 YearsUniversity of Colorado, Denver
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: